To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Attention Deficit Hyperactivity Disorder: Drugs
Friday 25th July 2025

Asked by: Ian Lavery (Labour - Blyth and Ashington)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure an adequate supply of ADHD medication.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The Department has worked closely with industry stakeholders and, following extensive collaborative efforts, previous issues have been resolved, and all strengths of lisdexamfetamine, atomoxetine capsules, atomoxetine oral solution, guanfacine prolonged-release tablets, and methylphenidate prolonged-release tablets are now available. We are working to resolve a remaining issue for Equasym XL capsules, and anticipate that this issue to be resolved in August 2025.

We continue to support the NHS England ADHD taskforce, which brings together expertise from the National Health Service, education, and justice sectors to coordinate a system-wide response to rising demand. In collaboration with NHS England’s national attention deficit hyperactivity disorder (ADHD) data improvement plan, we are developing future growth forecasts to support improved demand planning. These forecasts will be shared with industry to help ensure a more responsive and sustainable supply of ADHD medicines. In parallel, we are also engaging with new suppliers for ADHD medicines to increase supply capacity and resilience.

The Department also maintains and regularly updates a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website. This resource supports prescribers and dispensers in making informed decisions with patients. The list is available at the following link:

www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd


Written Question
Death: Poverty
Tuesday 11th March 2025

Asked by: Ian Lavery (Labour - Blyth and Ashington)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what the statistics are for poverty related death per local area in each of the last five years.

Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)

There are no official published statistics on poverty-related deaths. Statistics on deaths from specific causes are based on the medical causes of death recorded on a death certificate, which are coded using the International Classification of Diseases (ICD). Although poverty is included within the ICD it is rarely coded as a cause of death.

Estimates of the number of deaths due to some factors that influence mortality but are not always stated as a cause of death, such as smoking, can be made. However, there is no agreed definition of a poverty-related death for use within Government, and no official statistics on potential numbers.


Written Question
Drugs: Shortages
Monday 3rd March 2025

Asked by: Ian Lavery (Labour - Blyth and Ashington)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to help tackle shortages of medications due to supply issues in the North East of England.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The Department monitors and manages medicine supply at a national level so that stocks remain available to meet regional and local demand. Information on stock levels within the North East of England is not held centrally.

Most supply issues can be managed to avoid shortages, and while we can’t always prevent supply issues from occurring, we do have a range of well-established processes and tools to manage them when they arise, to mitigate risks to patients.

The resilience of the United Kingdom’s supply chains is a key priority, and the Department and NHS England are committed to helping to build long term supply chain resilience for medicines. We are continually learning and seeking to improve the way we work to both manage and help prevent supply issues and avoid shortages. The Department, working closely with NHS England, is taking forward a range of actions to improve our ability to mitigate and manage shortages and strengthen our resilience. As part of that work, we continue to engage with industry, the Medicines and Healthcare products Regulatory Agency, and other colleagues across the supply chain as we progress work to co-design and deliver solutions.


Written Question
Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction
Monday 9th September 2024

Asked by: Ian Lavery (Labour - Blyth and Ashington)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to support sufferers of post SSRI sexual dysfunction.

Answered by Andrew Gwynne

Patients can visit either their general practice (GP), or a sexual health clinic, for support with erectile dysfunction. Anyone experiencing mental health issues, including those related to selective serotonin reuptake inhibitor (SSRI) use, is encouraged to seek help by consulting to their GP or by self-referring to their local NHS Talking Therapies service.

The product information for individual SSRI medicines describe a range of side-effects, including potential sexual dysfunction during treatment. Some products specifically note that these symptoms may persist even after discontinuing the medication. Patients are encouraged to discuss the benefits and risks associated with medicines with their prescriber for individual support.

As with all medicines, the evidence available for the safety of antidepressants remains under continual review by the Medicines and Healthcare products Regulatory Agency after they are authorised for use. In response to patient and family feedback, an Expert Working Group under the Commission of Human Medicines has been established. This group is currently considering the risk minimisation measures for antidepressants in relation to suicide and suicidal behaviour. The scope of this review has been expanded to include the risk of persistent sexual dysfunction after stopping the medication for all 30 antidepressants currently marketed in the United Kingdom.

The National Institute for Health and Care Research (NIHR) has funded previous studies focused on the effects of antidepressant medication on sexual function. For example, a systematic review to determine the effectiveness of management strategies for sexual dysfunction caused by antidepressants, and to determine the adverse effects and acceptability of these different management strategies.


Written Question
Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction
Thursday 5th September 2024

Asked by: Ian Lavery (Labour - Blyth and Ashington)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what research his Department is undertaking on permanent antidepressant induced sexual dysfunction.

Answered by Andrew Gwynne

The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR has funded previous studies focused on the effects of antidepressant medication on sexual function. For example, a systematic review to determine the effectiveness of management strategies for sexual dysfunction caused by antidepressants, and to determine the adverse effects and acceptability of these different management strategies. The NIHR is not currently funding any research with a focus on the permanency of antidepressant induced sexual dysfunction. The NIHR welcomes funding applications for research into any aspect of human health, including antidepressant-associated sexual dysfunction.


Written Question
Poverty: North East
Wednesday 31st July 2024

Asked by: Ian Lavery (Labour - Blyth and Ashington)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many children are being treated for poverty related illness in (a) Blyth and Ashington constituency and (b) the North East.

Answered by Andrew Gwynne

The data requested is not held by NHS England, as poverty is not a metric used for the classification of illness. Although poverty is not a direct cause of specific health conditions, it can be a risk factor for physical and mental ill health. The Government is committed to raising the healthiest generation of children in history. This will include delivery of an ambitious strategy to reduce child poverty, tackle the root causes, and give every child the best start at life.


Written Question
Pharmacy: Northumberland
Tuesday 30th January 2024

Asked by: Ian Lavery (Labour - Blyth and Ashington)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information her Department holds on the number of pharmacies in Northumberland that were contracted to be open for 100 hours a week on 23 January 2024.

Answered by Andrea Leadsom

On 31 December 2023, there were 68 pharmacies in Northumberland, including five that were contracted to be open for at least 72 hours. On 31 December 2019, there were 71 pharmacies in Northumberland, including six that were contracted to be open for at least 100 hours.

In May 2023 new legislation came into force which enabled 100-hour pharmacies to reduce their minimum number of opening hours to 72, to support the viability of those pharmacies and prevent them from closing.


Written Question
Pharmacy: Northumberland
Tuesday 30th January 2024

Asked by: Ian Lavery (Labour - Blyth and Ashington)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information her Department holds on the number of pharmacies contracted to be open for 100 hours a week in Northumberland in 2019.

Answered by Andrea Leadsom

On 31 December 2023, there were 68 pharmacies in Northumberland, including five that were contracted to be open for at least 72 hours. On 31 December 2019, there were 71 pharmacies in Northumberland, including six that were contracted to be open for at least 100 hours.

In May 2023 new legislation came into force which enabled 100-hour pharmacies to reduce their minimum number of opening hours to 72, to support the viability of those pharmacies and prevent them from closing.


Written Question
Pharmacy: Northumberland
Tuesday 30th January 2024

Asked by: Ian Lavery (Labour - Blyth and Ashington)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information her Department holds on the number of pharmacies open in Northumberland in 2019.

Answered by Andrea Leadsom

On 31 December 2023, there were 68 pharmacies in Northumberland, including five that were contracted to be open for at least 72 hours. On 31 December 2019, there were 71 pharmacies in Northumberland, including six that were contracted to be open for at least 100 hours.

In May 2023 new legislation came into force which enabled 100-hour pharmacies to reduce their minimum number of opening hours to 72, to support the viability of those pharmacies and prevent them from closing.


Written Question
Pharmacy: Northumberland
Tuesday 30th January 2024

Asked by: Ian Lavery (Labour - Blyth and Ashington)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information her Department holds on the number of pharmacies in Northumberland.

Answered by Andrea Leadsom

On 31 December 2023, there were 68 pharmacies in Northumberland, including five that were contracted to be open for at least 72 hours. On 31 December 2019, there were 71 pharmacies in Northumberland, including six that were contracted to be open for at least 100 hours.

In May 2023 new legislation came into force which enabled 100-hour pharmacies to reduce their minimum number of opening hours to 72, to support the viability of those pharmacies and prevent them from closing.